2
|
Nose Y, Kagawa Y, Hata T, Mori R, Kawai K, Naito A, Sakamoto T, Murakami K, Katsura Y, Ohmura Y, Masuzawa T, Takeno A, Takeda Y, Kato T, Murata K. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study. Cancer Chemother Pharmacol 2020; 86:427-433. [PMID: 32816155 DOI: 10.1007/s00280-020-04129-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 08/11/2020] [Indexed: 01/02/2023]
Abstract
PURPOSE Trifluridine/tipiracil (FTD/TPI) improves the overall survival (OS) of metastatic colorectal cancer (mCRC) patients. Additionally, FTD/TPI plus bevacizumab (BEV) has demonstrated promising efficacy for mCRC patients who are refractory to standard chemotherapy. Chemotherapy-induced neutropenia (CIN) has been reported to be an indicator of efficacy for FTD/TPI. This study investigated whether CIN was an indicator of efficacy for FTD/TPI plus BEV. METHODS We reviewed chemo-refractory mCRC patients who were treated with FTD/TPI alone (monotherapy) or FTD/TPI plus BEV (combination) at our institution and compared the safety and efficacy of the two. Progression-free survival (PFS) and OS were analyzed using Kaplan-Meier curves. We also investigated correlations between CIN and outcomes. RESULTS In total, 56 patients received FTD/TPI, among whom 24 and 32 were treated with monotherapy and combination therapy, respectively. The median PFS was 1.8 and 4.7 months for the monotherapy and combination arms, respectively (hazard ratio [HR]: 0.28; 95% confidence interval [CI]: 0.15-0.51; P < 0.001). The median OS was 6.3 and 11.7 months for the monotherapy and combination arms, respectively (HR 0.25; 95% CI 0.13-0.48; P < 0.001). CIN (Grade 3 or worse) developed in five (20.8%) and 17 (53.1%) patients from the monotherapy and combination arms, respectively (P = 0.030). Patients with CIN in the combination arm had improved PFS and OS compared with non-CIN patients (P = 0.033 and P = 0.045, respectively). CONCLUSIONS FTD/TPI plus BEV prolonged PFS and OS and had tolerable toxicity compared with FTD/TPI alone. CIN is an indicator of patients who will benefit from FTD/TPI plus BEV.
Collapse
Affiliation(s)
- Yohei Nose
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.,Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Yoshinori Kagawa
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.
| | - Taishi Hata
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
| | - Ryota Mori
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.,Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Kenji Kawai
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
| | - Atsushi Naito
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.,Department of Surgery, Osaka Police Hospital, Osaka, Japan
| | - Takuya Sakamoto
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
| | - Kohei Murakami
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
| | - Yoshiteru Katsura
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
| | - Yoshiaki Ohmura
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
| | - Toru Masuzawa
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
| | - Atsushi Takeno
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
| | - Yutaka Takeda
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
| | - Takeshi Kato
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.,Department of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan
| | - Kohei Murata
- Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
| |
Collapse
|
3
|
Houts AC, Ogale S, Sommer N, Satram-Hoang S, Walker MS. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens. J Gastrointest Cancer 2019; 50:69-77. [PMID: 29168112 DOI: 10.1007/s12029-017-0027-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
PURPOSE Patients with Kirsten rat sarcoma viral oncogene wild-type (KRAS WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) plus standard chemo backbones had comparable outcomes in phase III Cancer and Leukemia Group B (CALGB) 80405. We examined comparative effectiveness of B and C regimens in real-world community settings. METHODS This retrospective study examined progression-free survival (PFS) and OS in a US community sample of KRAS WT mCRC patients treated with first-line B (n = 254) or C (n = 146) regimens. Medical records from the Vector Oncology Data Warehouse were used. Disease progression was determined from patient charts. OS was measured from the start of first-line treatment until death. RESULTS There were no significant difference in either PFS or OS respectively between B-treated compared to C-treated patients (HR = 1.324, 95% CI 0.901, 1.947; HR = 1.080, 95% CI 0.721, 1.617). More B patients received oxaliplatin backbones (74.8 vs. 36.3%), and more C patients received irinotecan backbones (51.4 vs. 20.1%), ps < 0.001. Multivariate survival analyses showed a significant difference indicating a greater risk for death among C-treated patients with right-sided tumors vs. left-sided tumors (HR = 2.263, 95% CI 1.394, 3.673, p = 0.0009), but not for B-treated patients (HR = 1.209, 95% CI 0.825, 1.771, p = 0.3297). CONCLUSIONS Consistent with CALGB 80405, median PFS and OS for these community oncology KRAS WT mCRC patients treated with first-line B or C regimens did not differ significantly.
Collapse
Affiliation(s)
- Arthur C Houts
- Vector Oncology, 6555 Quince, Suite 400, Memphis, TN, 38119, USA.
| | - Sarika Ogale
- Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA
| | - Nicolas Sommer
- Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA
| | - Sacha Satram-Hoang
- Q.D. Research, Inc., 8777 Auburn Folsom Rd., Suite C501, Granite Bay, CA, 95746, USA
| | - Mark S Walker
- Vector Oncology, 6555 Quince, Suite 400, Memphis, TN, 38119, USA
| |
Collapse
|
4
|
Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, Guo W, Han SW, Liu T, Park YS, Shi C, Bai Y, Bi F, Ahn JB, Qin S, Li Q, Wu C, Ma D, Lin D, Li J. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol 2018; 36:350-358. [DOI: 10.1200/jco.2017.74.3245] [Citation(s) in RCA: 104] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Trifluridine/tipiracil (TAS-102) was effective in patients with metastatic colorectal cancer (mCRC) in a phase II Japanese trial. This regional trial evaluated the efficacy and safety of trifluridine/tipiracil in Asian patients with mCRC with or without exposure to biologic therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase III trial was conducted at 30 sites in China, the Republic of Korea, and Thailand. Patients ≥ 18 years old with histologically or cytologically confirmed adenocarcinoma of the colon or rectum and known KRAS status who were refractory or intolerant to two or more prior chemotherapy regimens were enrolled. Eligible patients were randomly assigned (2:1 ratio; minimization method) to receive trifluridine/tipiracil (twice per day orally; 5 days on and 2 days off for 2 weeks, followed by 14 days off per cycle) or placebo. The primary end point was overall survival (intent-to-treat population). Results Between October 16, 2013, and June 15, 2015, 406 patients were randomly assigned to receive trifluridine/tipiracil (n = 271) or placebo (n = 135). Risk of death was significantly lower in the trifluridine/tipiracil arm than in the placebo arm (hazard ratio for death, 0.79; 95% CI, 0.62 to 0.99; log-rank P = .035). Median overall survival was significantly longer in the trifluridine/tipiracil than in the placebo arm (7.8 months [95% CI, 7.1 to 8.8 months] v 7.1 months [95% CI, 5.9 to 8.2 months], respectively), for a median survival follow-up time of 13.8 months (95% CI, 13.1 to 15.3 months) compared with 13.4 months (95% CI, 11.6 to 17.3 months), respectively. The incidence of serious adverse events was similar between the arms (trifluridine/tipiracil, n = 63 [23.2%]; placebo, n = 32 [23.7%]). No treatment-related deaths were reported. Conclusion Trifluridine/tipiracil has a statistically significant survival benefit compared with placebo in Asian patients with mCRC refractory or intolerant to standard chemotherapies, regardless of exposure to biologic therapy. The safety profile is similar to previous reports.
Collapse
Affiliation(s)
- Jianming Xu
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Tae Won Kim
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Lin Shen
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Virote Sriuranpong
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Hongming Pan
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Ruihua Xu
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Weijian Guo
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Sae-Won Han
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Tianshu Liu
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Young Suk Park
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Chunmei Shi
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Yuxian Bai
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Feng Bi
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Joong Bae Ahn
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Shukui Qin
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Qi Li
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Changping Wu
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Dong Ma
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Donghu Lin
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| | - Jin Li
- Jianming Xu, Affiliated Hospital Cancer Centre, Academy of Military Medical Sciences (The 307 Hospital Cancer Centre of People’s Liberation Army); Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Hongming Pan, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou; Ruihua Xu, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou; Weijian
| |
Collapse
|
7
|
Porru M, Zizza P, Franceschin M, Leonetti C, Biroccio A. EMICORON: A multi-targeting G4 ligand with a promising preclinical profile. Biochim Biophys Acta Gen Subj 2016; 1861:1362-1370. [PMID: 27838395 DOI: 10.1016/j.bbagen.2016.11.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 11/07/2016] [Accepted: 11/08/2016] [Indexed: 02/09/2023]
Abstract
BACKGROUND During the last decade, guanine G-rich sequences folding into G-quadruplex (G4) structures have received a lot of attention and their biological role is now a matter of large debate. Rising amounts of experimental evidence have validated several G-rich motifs as molecular targets in cancer treatment. Despite that an increasing number of small molecules has been reported to possess excellent G4 stabilizing properties, none of them has progressed through the drug-development pipeline due to their poor drug-like properties. In this context, the identification of G4 ligands with more favorable pharmacological properties and with a well-defined target activity could be fruitful for anticancer therapy application. SCOPE OF REVIEW This manuscript outlines the current state of knowledge regarding EMICORON, a G4-interactive molecule structurally and biologically similar, on the one side, to coronene and, on the other side, to a bay-monosubstituted perylene. MAJOR CONCLUSIONS Overall this work evidences that EMICORON, a new promising G4 ligand, possesses a marked antitumoral activity both standing alone and in combination with chemotherapeutics. Moreover, EMICORON represents a good example of multimodal class of antitumoral drug, able to simultaneously affect multiple targets participating in several distinct signaling pathways, thus simplifying the treatment modalities and improving the selectivity against cancer cells. GENERAL SIGNIFICANCE Due to the importance of G4 forming sequences in crucial biological processes participating in tumor progression, their successful targeting with small molecules could represent a very important innovation in the development of effective therapeutic strategies against cancer. This article is part of a Special Issue entitled "G-quadruplex" Guest Editor: Dr. Concetta Giancola and Dr. Daniela Montesarchio.
Collapse
Affiliation(s)
- Manuela Porru
- SAFU, Department of Research, Diagnosis and Innovative Technologies, Translational Research Area, Regina Elena National Cancer Institute, Rome, Italy
| | - Pasquale Zizza
- Oncogenomic and Epigenetic Unit, Regina Elena National Cancer Institute, Italy.
| | - Marco Franceschin
- Department of Chemistry, University of Rome "La Sapienza", Rome, Italy
| | - Carlo Leonetti
- SAFU, Department of Research, Diagnosis and Innovative Technologies, Translational Research Area, Regina Elena National Cancer Institute, Rome, Italy
| | - Annamaria Biroccio
- Oncogenomic and Epigenetic Unit, Regina Elena National Cancer Institute, Italy.
| |
Collapse
|